Figure 5.
OS and disease-specific survival by treatment in the 3 MZL subtypes: NMZL, ENMZL, and SMZL. R-monotherapy, rituximab-monotherapy.

OS and disease-specific survival by treatment in the 3 MZL subtypes: NMZL, ENMZL, and SMZL. R-monotherapy, rituximab-monotherapy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal